Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH018 in Combination With Toripalimab in Advanced Solid Tumors
NCT04914286Phase 2Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of gfh018 in solid tumor (advanced stage), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), gallbladder cancer, pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Started Oct 2021; status: completed.
02
Drugs
gfh018
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gallbladder cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04914286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914286.